Key Takeaways
- Shares of Abivax plummeted over 32% Tuesday following Phase 3 trial results for obefazimod, its ulcerative colitis treatment, which demonstrated exceptional effectiveness but raised concerns over rare cancer occurrences.
- The drug achieved approximately 51% clinical remission rates across both dosage groups, significantly surpassing the 10.4% placebo response and exceeding Wall Street projections.
- Researchers identified cancers including prostate, breast, and skin malignancies in a handful of participants receiving the elevated dose, although Abivax maintains no causal connection to the medication.
- Jefferies slashed its rating to Hold, pointing to the cancer-related uncertainty and absence of upcoming catalysts throughout the next twelve-month period.
- Stifel’s research team characterized the safety concern as a “potential labelling overhang” without clear causation, maintaining that regulatory approval remains probable.
Shares of Abivax experienced a dramatic 32% decline Tuesday after the biotechnology firm released Phase 3 trial outcomes for its oral ulcerative colitis medication that analysts characterized as industry-leading — yet were eclipsed by several uncommon malignancy cases among study subjects.
The Paris-based company’s shares plummeted more than 32% during European market hours by midday, erasing billions in valuation for a biotech that had been trading around $130 just one day earlier — a remarkable climb from below $10 twelve months prior.
The medication driving this volatile reaction is obefazimod, an oral once-daily treatment that functions by elevating miR-124 expression, a molecule that regulates immune responses. The therapeutic approach aims to reduce inflammatory bowel disease inflammation while avoiding widespread immune system suppression.
During the 44-week Phase 3 clinical investigation, approximately 50.8% of subjects receiving the 25mg dosage and 51.3% taking the 50mg formulation reached clinical remission status. Comparatively, the placebo group achieved just 10.4%.
These figures substantially exceeded Wall Street forecasts and, per Stifel’s analyst Damien Choplain, demonstrate superiority over existing injectable treatment options, which generally produce placebo-adjusted remission outcomes ranging between 19% and 32%.
Cancer Findings Trigger Market Panic
The complication emerged from several malignancy discoveries — affecting prostate, breast, and skin tissues — identified among subjects taking the elevated dosage. Company representatives stated these incidents were assessed as unconnected to the treatment and showed no concentration in any particular organ system.
Despite this clarification, the market reaction was severe. Jefferies lowered its recommendation to Hold, asserting the uncertainty “will be real,” especially given the absence of significant data releases anticipated over the coming year.
Choplain from Stifel recognized the finding “cannot be ignored” yet positioned it as a regulatory labeling matter rather than definitive causation. He referenced AbbVie’s Rinvoq — an oral IBD medication carrying a black box malignancy warning — which nevertheless produced $8.3 billion in sales during the previous year.
Thomas Smith from Leerink Partners observed that established IBD medications Stelara and Entyvio already include label language regarding theoretical cancer risks, and comparable labeling for obefazimod wouldn’t render it “commercially uncompetitive” considering its superior effectiveness profile.
Regulatory Submission Remains Scheduled — At Present
Abivax announced intentions to submit regulatory applications during Q4 2025. Company leadership continues asserting the malignancy occurrences don’t constitute a causal safety threat.
Smith stated the effectiveness results “clearly exceeded expectations,” satisfied all primary and secondary objectives, and distinguishes the medication from rival treatments.
Whether regulatory authorities accept this interpretation — and the FDA’s approach to evaluating the cancer signal during assessment — represents the critical upcoming question for shareholders.
By Tuesday’s close, the equity had surrendered nearly all appreciation accumulated over the preceding twelve months within one trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
